Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 4NIH 2NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Specimen Handling 40Magnetic Resonance Spectroscopy 30Carboplatin 14Biopsy 14Radiation 13Cyclophosphamide 13Radiotherapy 11daratumumab 10Vincristine 10Dexamethasone 10Surgical Procedures, Operative 9Etoposide 9Lenalidomide 8X-Rays 7Observation 7Leucovorin 7Irinotecan 7Doxorubicin 7Cisplatin 7durvalumab 6dexamethasone acetate 6dexamethasone 21-phosphate 6auricularum 6Watchful Waiting 6Standard of Care 6Radiosurgery 6Practice Guidelines as Topic 6Docetaxel 6Calcium Dobesilate 6pembrolizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × NETWORK × Hyaluronoglucosaminidase × Clear all
NCT05289687 2026-05-05

Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

Eastern Cooperative Oncology Group

Phase 2 Recruiting
20 enrolled
LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡